Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 7/2003

01-11-2003

Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor

Authors: Jiro Okami, Shoji Nakamori, Nobuaki Hiraoka, Masanori Tsujie, Nobuyasu Hayashi, Hirofumi Yamamoto, Yoshiyuki Fujiwara, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Masato Sakon, Morito Monden

Published in: Clinical & Experimental Metastasis | Issue 7/2003

Login to get access
Metadata
Title
Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor
Authors
Jiro Okami
Shoji Nakamori
Nobuaki Hiraoka
Masanori Tsujie
Nobuyasu Hayashi
Hirofumi Yamamoto
Yoshiyuki Fujiwara
Hiroaki Nagano
Keizo Dono
Koji Umeshita
Masato Sakon
Morito Monden
Publication date
01-11-2003
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 7/2003
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1027319903359

Other articles of this Issue 7/2003

Clinical & Experimental Metastasis 7/2003 Go to the issue

OriginalPaper

IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-α and DTIC

OriginalPaper

Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma

OriginalPaper

Biological properties and gene expression associated with metastatic potential of human osteosarcoma

OriginalPaper

Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells

OriginalPaper

Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase

OriginalPaper

Real-time imaging of individual fluorescent-protein color-coded metastatic colonies in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits